Literature DB >> 27742595

Development of biodegradable polyesters with various microstructures for highly controlled release of epirubicin and cyclophosphamide.

K Żółtowska1, U Piotrowska2, E Oledzka3, U Luchowska4, M Sobczak5, A Bocho-Janiszewska6.   

Abstract

In this study, "predominantly isotactic", disyndiotactic, and atactic polylactides (PLAs) and poly(ε-caprolactone)s (PCLs) were loaded with anticancer agents, epirubicin (EPI) and cyclophosphamide (CYCLOPHO), to investigate their properties as highly controlled delivery devices. It was found that the kinetic release of drugs from the obtained polyester matrices tested in vitro at 37°C and pH7.4 was strongly dependent on average molecular weight (Mn) of the polymers as well as the PLAs' microstructure. EPI and CYCLOPHO were released from various obtained matrices according to the diffusion, diffusion-degradation, and degradation mechanisms in a rather regular and continuous manner. Importantly, in some cases, the kinetics of the EPI and CYCLOPHO release was nearly zero-order, suggesting predominantly polymer degradation. It is shown that the drug release profiles can be tailored by a controlled design of the microstructure and Mn of polyesters, allowing use of the synthesized matrices for the development of highly controlled biodegradable anticancer drug delivery systems.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anticancer drug delivery systems; Biodegradable and bioresorbable biomedical polyesters; Controlled release; Cyclophosphamide; Epirubicin

Mesh:

Substances:

Year:  2016        PMID: 27742595     DOI: 10.1016/j.ejps.2016.10.014

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  1 in total

1.  A Comprehensive Investigation of the Structural, Thermal, and Biological Properties of Fully Randomized Biomedical Polyesters Synthesized with a Nontoxic Bismuth(III) Catalyst.

Authors:  Izabela M Domańska; Anna Zgadzaj; Sebastian Kowalczyk; Aldona Zalewska; Ewa Oledzka; Krystyna Cieśla; Andrzej Plichta; Marcin Sobczak
Journal:  Molecules       Date:  2022-02-08       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.